• Collaboration results in platform to help researchers overcome challenges in MSC research

• NextCell-Cord RUO cells designed for delivery as cryopreserved and sold as an individual product or bundled with PRIME-XV media from FUJIFILM Biosciences

SANTA ANA, Calif., USA and HUDDINGE, SWEDEN – FUJIFILM Biosciences, a global leader in the life science market, and NextCell Pharma AB, a clinical-stage company specializing in cell therapy using umbilical cord mesenchymal stromal cells (MSC), today announced a global commercial launch resulting from their strategic collaboration. The offering consists of FUJIFILM Biosciences’ PRIME-XV MSC Expansion XSFM medium and NextCell’s first commercial product, NextCell-Cord RUO, a research-use-only (RUO) MSC product derived from umbilical cord tissue. [Read more…]

If you’ve ever run a clean experiment on paper but ended up with messy, confusing results, you’re not alone. One of the most common frustrations researchers face is unexpected bands or signals caused by polyclonal antibody binding to off-target proteins. It’s especially tricky because polyclonal antibodies are widely used for their sensitivity, yet that same strength can quickly turn into a drawback. [Read more…]

The 2026 biotech conferences calendar is one of the densest years biopharma and the broader life sciences industry have seen.

FDA approval velocity remains high. Inflation Reduction Act implementation is entering a more consequential phase. Generative AI is moving from R&D experimentation into operational deployment. And biotech investment trends point to a re-opening capital environment after a multi-year reset.

All of that translates into a packed year of events competing for commercial, R&D, investor, and executive attention. [Read more…]